What was filed
Aurobindo Pharma disclosed that A1 Biochem Labs (India) Private Limited, a step-down subsidiary, subscribed to the full initial share capital of A1 Biochem USA Inc in the United States on September 11, 2026. The step continues the acquisition of the A1 Biochem Group, first flagged on July 23, 2026. A1 Biochem USA Inc was incorporated on August 27, 2026 and has yet to commence business, so no turnover history exists. The consideration was entirely in cash, and per the filing no governmental or regulatory approvals were required.
What the new entity will do
The US company is intended to carry out contract research and development services from the United States, as part of the broader A1 Biochem Group acquisition. Because A1 Biochem Labs (India) is a subsidiary of Apitoria Pharma Private Limited, itself a wholly owned subsidiary of Aurobindo, the company classified the transaction as a related-party transaction. It noted that the promoters and promoter group have no interest in the transaction.
Scale and context
This is a structural step rather than a large outbound deal — the subscription establishes a wholly owned US research vehicle at the initial share capital level, giving Aurobindo a US-based footprint for contract research and development work as it builds out the A1 Biochem Group platform.